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Abstract
Sepsis is a systemic inflammatory response that can lead to tissue damage and death. In order to increase our understanding of 
sepsis, experimental models are needed that produce relevant immune and inflammatory responses during a septic event. We 
describe a lipopolysaccharide tolerance mouse model to characterize the cellular and molecular alterations of immune cells during 
sepsis. The model presents a typical lipopolysaccharide tolerance pattern in which tolerance is related to decreased production 
and secretion of cytokines after a subsequent exposure to a lethal dose of lipopolysaccharide. The initial lipopolysaccharide 
exposure also altered the expression patterns of cytokines and was followed by an 8- and a 1.5-fold increase in the T helper 
1 and 2 cell subpopulations. Behavioral data indicate a decrease in spontaneous activity and an increase in body temperature 
following exposure to lipopolysaccharide. In contrast, tolerant animals maintained production of reactive oxygen species and 
nitric oxide when terminally challenged by cecal ligation and puncture (CLP). Survival study after CLP showed protection in 
tolerant compared to naive animals. Spleen mass increased in tolerant animals followed by increases of B lymphocytes and 
subpopulation Th1 cells. An increase in the number of stem cells was found in spleen and bone marrow. We also showed that 
administration of spleen or bone marrow cells from tolerant to naive animals transfers the acquired resistance status. In con-
clusion, lipopolysaccharide tolerance is a natural reprogramming of the immune system that increases the number of immune 
cells, particularly T helper 1 cells, and does not reduce oxidative stress.
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Introduction
Lipopolysaccharide (LPS) is one of the most potent 
known inducers of inflammation and exerts its effects via 
the Toll-like receptor (TLR) 4, which is essential for the 
recognition of distinct bacterial cell wall components (1-3). 
Inhibition of TLR signaling by inducible negative regulators, 
anti-inflammatory cytokines and alterations in the TLR sig-
naling complex has been attributed to the phenomenon of 
“LPS tolerance” (1). Endotoxin tolerance has been defined 
as reduced responsiveness to a LPS challenge following 
a first encounter with endotoxin (4,5). Tolerance to LPS 
involves the participation of macrophages and mediators 
such as glucocorticoids, prostaglandins, interleukin-10 (IL-
10), and transforming growth factor beta (4). However, the 
assumption that LPS tolerance is caused by a “generalized” 
down-regulation of cellular responses and mediator release 
is not accurate (4,6). A similar loss of LPS reactivity has 
been repeatedly reported in circulating leukocytes of septic 
patients (4,7). Studies of cellular signaling within leukocytes 
from septic patients have revealed numerous alterations 
similar to those observed in endotoxin-tolerant cells (4,7). 
However, the altered responsiveness to LPS of leukocytes 
from septic patients is not synonymous with LPS tolerance. 
The term “cellular reprogramming” is helpful in describing 
the immune status of circulating leukocytes during the es-
tablishment of endotoxin tolerance (4,8). Tolerance to LPS 
has been shown to protect against bacterial infections; it 
is a model of an adequate immune response in contrast to 
the deadly dysregulation of immune function in sepsis (4). 
In other studies, monophosphoryl lipid A has been used to 
produce tolerance and has been shown to protect animals 
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from subsequent infections (4,9).
Animal models represent a critical research bridge 
between experimental results from the laboratory and 
findings at the clinical level. Any disease, or intoxication, of 
humans that is established experimentally in animals should 
ideally mimic the natural sequelae seen in humans. The 
establishment of simple, economical, and robust animal 
models that can be used in different laboratories should 
facilitate the discovery of vaccines or therapies. One goal 
of the proposed murine model is to accelerate the develop-
ment of vaccines or therapies that target a select family of 
bacterial protein toxins. 
The aim of the present study was to evaluate a murine 
model of LPS tolerance. We characterized the complex 
cellular alterations associated with tolerance, including 
increased lymphocyte, monocyte and neutrophil prolifera-
tion. 
Material and Methods
The present study was approved by the Research Ethics 
Committee of the University of São Paulo School of Medicine 
(protocol #331/06). All animals were treated according to 
institutional rules for laboratory animal care. 
Unless otherwise indicated, reagents were purchased 
from Sigma-Aldrich (USA).
Induction of LPS tolerance
Six-week-old male BALB/c mice weighing 20 to 25 g 
were randomized into two groups. The naive group (N = 
47) received daily subcutaneous injections of 1 mL saline, 
and the tolerant group (N = 47) received daily subcutane-
ous injections of either 0.5 or 1 mg/kg LPS [Sigma-Aldrich 
(LPS Escherichia coli serotype 026:B6) catalogue number 
L3755] for 5 days and was allowed to rest for 2 days.
Lethal LPS challenge
Following induction of LPS tolerance and a 2-day rest, on 
day 8 some animals received either the lethal dose of LPS 
(20 mg/kg; 80% mortality in naive mice) or a supramaximal 
LPS dose (40 mg/kg; 100% mortality in naive mice) ip. Some 
animals from the tolerant and naive groups were sacrificed 
at 0 (zero), 2, 4, 6, and 8 h after the lethal challenges for 
biochemical measurements and cytokine analysis. 
Cecal ligation and puncture (CLP) model 
Mice were anesthetized with a mixture of ketamine (80 
mg/kg) and xylazine (10 mg/kg) given intraperitoneally. 
Under aseptic conditions, a 2-cm midline laparotomy was 
performed to allow exposure of the cecum with adjoining 
intestine. The cecum was tightly ligated with a 3.0 silk 
suture (Ethicon; Johnson & Johnson, USA) at its base, 
below the ileocecal valve, and was perforated twice (top 
and bottom) with an 18-gauge needle (Becton Dickinson, 
USA). The cecum was returned to the peritoneal cavity 
and the laparotomy was closed with 4.0 silk sutures. The 
animals were returned to their cages with free access to 
food and water.
Study of animal survival
Survival was assessed after CLP challenge or the ad-
ministration of a lethal dose of LPS. Each group comprised 
30 animals, and survival was assessed every 8 h up to 
72 h after LPS or CLP. After 72 h, there was no change 
in survival.
Measurement of cytokines
Blood was collected from 6 mice per group using tubes 
containing ethylenediamine tetraacetic acid (1 mg/mL). 
Blood was centrifuged, and the supernatant was harvested 
to identify secreted cytokines. Production of IL-6, IL-10, 
macrophage inflammatory protein 2 (MIP-2), tumor necrosis 
factor alpha (TNF-α) and IL-1β was evaluated by enzyme-
linked immunosorbent assay (ELISA) using a DuoSet kit 
(R&D Systems, USA). We performed all ELISA assays at 
the same time to avoid any kind of variation.
Reverse transcriptase-polymerase chain reaction
A reverse transcriptase-polymerase chain reaction 
(RT-PCR) assay was performed to measure the differential 
mRNA expression of TNF-α, IL-10 and IL-1β in cells from 
naive and tolerant mice. Primer sequences were designed 
using information accessed from GenBank of the National 
Center for Biotechnology Information (NCBI, www.ncbi.
nlm.nih.gov). For semi-quantitative PCR analysis, the 
housekeeping glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene sequence was used as a reference.
PCR analysis 
The PCR products were analyzed on 1.5% agarose gels 
containing 0.5 µg/mL ethidium bromide and electrophoresed 
for 1 h at 100 V. Gels were photographed using a Kodak 
DC120 Zoom Digital Camera System (Eastman Kodak, 
USA). Images were processed and analyzed with the Kodak 
Digital Science 1D Image Analysis software (Eastman 
Kodak). Band intensities were absorbance normalized with 
respect to GAPDH expression. Samples from naive mice 
(N = 6) received an arbitrary value of 1, and the values for 
samples from tolerant mice (N = 6) were in relation to those 
for the respective naive animals.
Thiobarbituric acid-reactive substances
Formation of thiobarbituric acid-reactive substances 
(TBARS) was used to quantify the lipid peroxidation in tis-
sues. Tissues were homogenized (100 mg/mL) in 1.15% 
KCl. A total of 200 mL of the homogenates was then added 
to a reaction mixture consisting of 1.5 mL 0.8% thiobarbituric 
acid, 200 µL 8.1% sodium dodecyl sulfate, 1.5 mL 20% 
acetic acid, pH 3.5, and 600 µL distilled water. The mixture 
was then heated to and maintained at 90°C for 45 min. After 
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cooling to room temperature, the samples were cleared by 
centrifugation at 10,000 g (10 min) and their absorbance was 
measured at 532 nm, using 1,1,3,3-tetramethoxypropane 
(Sigma-Aldrich) as an external standard. The level of lipid 
peroxides was reported as µmol TBARS/mg protein.
Nitrite and nitrate
Plasma nitrite and nitrate (NOx) levels were measured 
by the classic Griess method. After being passed through 
50-kDa ultrafilters, 40 μL plasma was diluted with 240 μL 
assay buffer and mixed with 10 μL cofactor and 10 μL nitrate 
reductase (NOx colorimetric assay kit; Cayman Chemical, 
USA). After the plasma had been maintained at room tem-
perature for 3 h to convert nitrate to nitrite, total nitrite was 
measured at 540 nm absorbance by reaction with Griess 
reagent (sulfanilamide and naphthalene-ethylene diamine 
dihydrochloride). Amounts of plasma nitrite were estimated 
by a standard curve obtained from enzymatic conversion 
of NaNO3 to nitrite.
Spleen tissue preparation 
Spleen tissue (50 mg) was pulverized in liquid nitro-
gen and homogenized in RIPA buffer (10 mM Tris-HCl, 
pH 7.5), 1% tergitol, 0.1% sodium dodecyl sulfate, 1% 
Na-deoxycholate, 150 mM NaCl, 40 µg/mL phenylmeth-
ylsulfonyl fluoride, and 10 µg/mL pepstatin (Sigma, USA). 
Samples were centrifuged at 14,000 g for 45 min and protein 
concentrations from supernatants were determined by the 
Bradford method (10,11). 
Quantification of leukocytes
For flow cytometry analysis, spleen tissue was gently 
ground to dissociate cells. After hypotonic lysis of red blood 
cells, and following cell membrane permeabilization with 
saponin, leukocytes were incubated for 30 min at room 
temperature with fluorescein isothiocyanate-labeled anti-
mouse monoclonal antibodies specific for murine CD3+ and 
CD4+ T-lymphocytes, and phycoerythrin-labeled antibodies 
to TNF-α, interferon-γ, IL-10, and IL-4. The analysis was 
performed using the Coulter EPICS XL-MCL flow cytometer 
(Beckman Coulter, UK) with gating on lymphocytes using 
characteristic forward and side scatter.
Pluripotent cells 
The anti-apoptotic transcription factor Octamer-4 (Oct-4) 
is a member of the Pit-Oct-Unc family and a marker of pluri-
potent cells. The undifferentiated state of embryonic stem 
cells is characterized by a high level of Oct-4 expression. To 
determine levels of Oct-4, we used an embryonic stem cell 
recognition kit that includes antibodies to Oct-4 and SSEA-
1 (ES Cell Marker Sample Kit; Chemicon, USA). In brief, 
spleen cells were allowed to adhere to glass slides, after 
which they were washed twice with rinse buffer (TBST, 20 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween 20). Cells 
were then fixed with paraformaldehyde and permeabilized 
with 0.1% Triton X-100. Nonspecific markers were blocked 
with 5% bovine serum albumin, and the cells were incubated 
with primary antibody (anti-Oct-1 or anti-SSEA-1) at room 
temperature for 1 h. After three washes in TBST, the cells 
were incubated with fluorescein isothiocyanate-conjugated 
secondary antibody for 30 min. Cells were mounted on 
glass slides with antifade solution.
The slides were viewed under epifluorescence micros-
copy using a Zeiss Axioplan II microscope (Carl Zeiss, 
Germany) with a reticulated lens (100 grids of 1 x 1 mm). 
In each of 20 random fields, we counted the number of 
Oct-4- or SSEA-1-labeled cells among 200 nucleated cells, 
and the result is reported as the percent of the total. Three 
independent examiners performed the counts, and the final 
value represents the mean ± SEM of those three measure-
ments. The digital images were recorded using a cooled 
charge-coupled device camera (PCO Computer Optics, 
Germany), and analyzed using the ISIS program (MetaSys-
tems, Germany). The final magnification was 100X.
Transfer of tolerance 
Spleen tissue from tolerant mice was ground gently 
to dissociate cells. After hypotonic lysis of red blood cells 
and separation with Lymphoprep (Axis-Shield, Norway), 
leukocytes were resuspended in PBS buffer. Bone mar-
row cells were collected by flushing PBS into the marrow 
space. The collected mixture was resuspended in PBS for 
injection. During the first post-CLP hour, suspensions of 
cells from the spleen or bone marrow cells from tolerant or 
naive mice were injected intravenously into naive animals 
(40,000 cells/animal).
Behavior and clinical parameters
Mice were placed under anesthesia (3% halothane for 
induction and 1.5% for maintenance in 30% O2 and 70% 
N2O). Using aseptic techniques, a temperature transmit-
ter (E-mitter; Mini Mitter, USA) was placed in the perito-
neal cavity via a midline incision. After surgery, mice were 
housed in individual cages, each with a running wheel and 
a telemetry system (Vitalview 4000 series; Mini Mitter). 
Temperature was monitored telemetrically. Signals were 
received by an antenna below the cage (ER-4000 Receiver; 
Mini Mitter) and relayed to a signal processor connected to 
a computer. Wheel revolutions were monitored magnetically 
and relayed to a signal processor connected to a computer. 
Measurements of mean temperature and accumulated 
wheel revolutions were collected every 1 min.
Statistical analysis
Data were analyzed using the InStat software (Graph-
Pad Software Inc., USA). Results are reported as means 
± SEM. Groups were compared by paired t-tests, as 
well as analysis of variance with the Tukey-Kramer post 
hoc test, when appropriate. For the study of survival, a 
log-rank test was used. Results were considered to be 
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statistically significant at P < 0.05. 
Results
Survival study
The rate of survival following lethal LPS challenges was 
higher in animals that received prior treatment with LPS 
(tolerant) than in those not so treated (naive), as can be 
seen in Figure 1A,B. All animals received the lethal dose 
of LPS (either 20 or 40 mg/kg). Overall survival for naive 
animals after 72 h was 10%. Tolerant mice previously treated 
with 0.5 mg/kg LPS had a survival rate of 60%, whereas 
animals that received treatment with 1 mg/kg LPS showed 
100% survival compared to controls.
Characterization of LPS tolerance 
In BALB/c mice, LPS induced tolerance in a dose-
dependent manner, as shown by the reduced mortality after 
a subsequent lethal dose of LPS (Figure 1A,B). In tolerant 
mice, production of proinflammatory cytokines (TNF-α, IL-1β 
and IL-6; Figure 2A-C, respectively) and of the chemokine 
MIP-2 (Figure 2D) decreased in comparison to naive mice. 
In contrast, there was no difference in plasma levels of 
the anti-inflammatory cytokine IL-10 (Figure 2E). Levels 
of plasma NO and ROS (as measured via their NOx and 
TBARS products) remained unaffected in tolerant animals 
following LPS challenge (Figure 3A,B).
Leukocyte analysis 
The spleen is the largest peripheral lymphatic organ 
and plays an important role in the inflammatory response. 
Following lethal LPS challenge (20 mg/kg), control (N = 10) 
and tolerant (N = 10) animals were submitted to splenectomy 
and the spleens were weighed. Tolerant animals presented 
higher spleen mass and a reduction in body weight relative 
to controls (Figure 4A,B). 
Compared with those of controls, the spleens of toler-
ant animals contained larger numbers of B cells and T 
lymphocytes (CD4+ and CD8+), as shown in Figure 5A-F. 
The concentration of neutrophils in the spleen and blood 
was also higher in tolerant animals (data not shown). To 
determine whether a specific cell population was stimulated 
by LPS tolerance, T cells were analyzed by flow cytometry. 
Expression of TNF-α, IFN-γ, IL-4, and IL-10 was measured 
from cytoplasm. An elevated number of Th1 (TNF-α and 
IFN-γ) lymphocytes (P < 0.05) was observed in tolerant 
compared to naive mice (Figure 5C-F). When animals were 
subjected to CLP, the spleens from the naive group exhibited 
a reduction in the number of cells containing TNF-α (Figure 
5C) compared with those from the LPS-tolerant group. In 
addition, tolerant animals presented higher numbers of 
CD4+ T cells expressing IFN-γ (Figure 5E), IL-4 and IL-10 
(Figure 5D,F) than did the controls. Compared with those of 
the controls, the spleens of tolerant animals also exhibited 
an increase in pluripotent cells that was maintained even 
after CLP challenge (Figure 6A). A significant reduction 
in mortality was observed when cells extracted from the 
spleens and bone marrow of tolerant mice were injected 
intravenously into naive animals previously subjected to 
CLP (Figure 6B). In contrast, the injection of spleen or 
bone marrow cells from naive animals did not confer any 
protection (Figure 6C). 
Clinical and behavioral change
The body weight of the experimental animals was mea-
sured daily during induction of tolerance and after lethal LPS 
challenge. There was a continuous reduction in the weight 
of the animals after each LPS dose, as shown in Figure 4. 
Control animals showed no weight change during the first 
five days. After the lethal dose of LPS, both groups showed 
some reduction in body weight, which was greater in the 
control group. Temperature and spontaneous activity were 
Figure 1. Lipopolysaccharide-induced tolerance in mice. BALB/c mice were treated daily with 0.5 or 1 mg/kg lipopolysaccharide (LPS; 
tolerant group, N = 30) or saline placebo (naive group, N = 30) for 5 days. On day 8, animals received either a lethal dose (20 mg/kg) 
or a supramaximal dose (40 mg/kg) of LPS. Animals tolerized by prior exposure to LPS had higher survival rates. A, Survival following 
a lethal dose of 20 mg/kg LPS. B, Survival following a supramaximal dose of 40 mg/kg LPS. Data are representative of 20 animals 
per group.
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Figure 2. Cytokine production. BALB/c mice were treated with 1 mg/kg lipopolysaccharide (LPS; tolerant group, N = 6) or saline pla-
cebo (naive group, N = 6) daily for 5 days. Following a lethal dose of LPS (20 mg/kg) on day 8, LPS-tolerant (T) and naive (N) animals 
were sacrificed at 0 (zero), 2, 4, 6, and 8 h to obtain cytokine data. Blood serum concentrations of cytokines: A, Tumor necrosis factor 
alpha, TNF-α; B, interleukin, IL-1β; C, IL-6; D, macrophage inflammatory protein 2, MIP-2, and E, IL-10. F, Absorbance of PCR-am-
plified products (TNF-α, IL-10 and IL-1β) are presented as the ratio cytokine/glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Data are representative of 10 animals per group. *P < 0.05 compared to naive mice (analysis of variance with the Tukey-Kramer post 
hoc test).
Figure 3. Thiobarbituric acid-reactive substances (TBARS) and nitrite/nitrate production. Oxidative stress response and nitric oxide 
production in lipopolysaccharide-tolerant animals (tolerant group) and controls (naive group). A, TBARS per mg of protein was used as 
an index of oxidative stress. B, Blood plasma concentration of nitrite and nitrate (NOx). Data are representative of N = 10 animals per 
group. There were no significant statistical differences (analysis of variance with the Tukey-Kramer post hoc test).
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Figure 4. Body and spleen weight. Body and spleen weight of BALB/c mice treated with 1 mg/kg lipopolysaccharide (LPS; tolerant 
group) or saline placebo (naive group) daily for 5 days. Animals received a lethal dose of LPS (20 mg/kg) on day 8, following a two-
day rest. A, Change in daily body weight among tolerant and naive animals. Data are reported as means ± SEM. *P < 0.05 compared 
to naive mice (analysis of variance with the Tukey-Kramer post hoc test). B, Spleen weight of tolerant and naive animals. *P < 0.05 
compared to naive mice (unpaired t-test).
Figure 5. Quantitative analysis of spleen cells. Spleen lymphocyte counts in lipopolysaccharide-tolerant mice (T) compared with naive 
mice (N) 6 h after cecal ligation and puncture for A, T lymphocytes; B, B lymphocytes; C, TNF-α-positive lymphocytes; D, IL-4-positive 
lymphocytes; E, interferon (IFN)-γ-positive lymphocytes, and F, IL-10-positive lymphocytes. These data were obtained from a flow 
cytometry comparison of cells from tolerant and naive animals. *P < 0.05 compared to naive mice (unpaired t-test).
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measured throughout the period of LPS tolerance induction 
(Figure 7A,B). Temperature data showed a progressive 
increase in mean body temperature following each LPS 
dose. The temperature response when the lethal LPS dose 
(20 mg/kg) was applied was substantially higher than that 
observed for previous stimuli (Figure 7A). Spontaneous 
movement was measured by wheel activity. Animals showed 
a reduction in spontaneous activity during LPS tolerance 
induction and a large reduction after administration of the 
lethal dose of LPS (Figure 7B). 
Discussion
A murine model of endotoxin tolerance offers an in vivo 
system for analyzing the regulatory feedback mechanisms 
involved in cytokine synthesis (5). Endotoxin tolerance has 
been divided into an early, non-immunological phase and 
a later immunological phase in which circulating antibod-
ies might play a significant role in endotoxin detoxification 
(12,13). Based on literature data, we hypothesized that 
LPS tolerance produces an “adaptation” of the innate 
immune response (1). Previous studies have presented 
conflicting findings regarding cytokine production during 
lethal LPS challenges, as well as regarding the extent to 
which tolerance provides resistance to infection (4). Most 
of these differences are due to differences in the model 
used, doses used to establish tolerance, injection times, 
administration routes, and the time of delay before restimula-
tion with LPS or infection (4-6,14,15). In the present study, 
we established and characterized a reliable murine model 
of endotoxin tolerance in which we applied subcutaneous 
injection of LPS for inducing tolerance. While intraperitoneal 
injections are commonly reported in the literature, they 
cannot exclude the chance that protection against CLP is a 
local effect, perhaps activating local macrophages and the 
large number of neutrophils located in the peritoneal cavity 
(4-6,14,15). Because stress produces glucocorticoids that 
down-regulate proinflammatory cytokines, we waited for 
Figure 6. Pluripotent cells and transfer of tolerance. Suspensions of spleen or bone marrow cells from lipopolysaccharide-tolerant 
BALB/c mice were injected intravenously in naive animals submitted to cecal ligation and puncture (CLP) or a sham procedure. A, 
Intensity of Oct-4 in a sample of pooled spleen and bone marrow cells from tolerant and naive mice under sham and CLP conditions 
(magnification, 100X). Mortality following CLP (B) was 100% in naive mice after 48 h, 50% in naive mice injected with spleen cells after 
72 h, and 40% in naive mice injected with bone marrow cells after 72 h. No protection against mortality following CLP was observed in a 
control group (C) of naive mice that received cells suspended from the spleens or bone marrow of naive mice. Data are representative 
of 10 animals per group. *P < 0.05 for the difference between tolerant and naive groups (log-rank test).
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two days after establishing tolerance before challenging 
animals with LPS or CLP (4,16). Our aim was to identify 
changes in cell populations and gene expression produced 
by tolerance and to discover novel protection mechanisms in 
addition to the known effects of glucocorticoids. Models that 
do not allow animals to rest prior to a re-exposure to LPS, 
and others in which CLP is performed during the cytokine 
storm and inflammatory response, can result in investiga-
tors analyzing immunosuppression or immunoparalysis 
rather than a true tolerance phenomenon (4,5,10,11,15). In 
addition, we established tolerance using two doses of LPS 
and found that protection is dose-dependent. 
LPS tolerance model
We report that LPS tolerance is associated with sub-
stantial and selective alterations in animal behavior and 
immune cells. In animals, LPS tolerance is a highly effective 
mechanism for protection against the lethal syndrome of 
severe sepsis and other diseases (4,5). This phenomenon, 
which seemingly prepares the organism for a subsequent 
infection, was originally described as a form of “blunted 
endotoxin-associated mortality” not necessarily related to 
cytokine production (5). The first aim of our study was to 
confirm that our procedure produced a reliable model of 
LPS tolerance. This was a critical step, due to the variety 
of tolerance models in the literature using different LPS 
doses, frequencies and periods (4,5). We established 
tolerance using two different doses of LPS. The mortality 
data demonstrate that the protective effect of LPS-induced 
tolerance is dose-dependent. A dose of 1 mg/kg LPS per day 
over 5 days provided complete protection in experimental 
animals, whereas a dose of 0.5 mg/kg per day provided 
only partial protection. We then measured the production 
of selected cytokines after animals had been challenged 
with a lethal dose of LPS. Because of economic and ethical 
constraints, cytokine analysis was performed using only the 
animals that achieved complete protection (i.e., the 1 mg/
Figure 7. Effect of lipopolysaccharide (LPS) tolerance on body temperature and exercise. BALB/c mice (N = 8) were injected daily 
(D1, D2, D3, D4, and D5) with 1 mg/kg LPS, followed by 2 days of rest (R1 and R2) and lethal (L) injection of LPS (20 mg/kg). Effect 
of treatment on (A) mean 24 h body temperature and (B) mean 24 h exercise wheel activity. Data are representative of 8 animals. *P 
< 0.05 vs control group (C); #P < 0.05 vs all other groups; §P < 0.05 vs D1 and D4; +P < 0.05 vs D1-D5 (analysis of variance with the 
Tukey-Kramer post hoc test).
kg group). We found that injection of lethal doses of LPS 
into mice results in transient increases in serum levels of 
TNF-α, IL-1β, IL-10, IL-6, and MIP-2. The data show that 
induction of tolerance produced a significant reduction in the 
plasma levels of TNF-α, IL-1β, IL-6, and MIP-2, but not of 
IL-10. There are conflicting data in the literature regarding 
IL-1β; some investigators have reported that production of 
IL-1β decreases in tolerant animals, whereas others found 
no difference (4,5). Our experiments showed that, in animals 
tolerized with a high LPS induction dose, IL-1β production 
decreased following administration of the lethal LPS dose. In 
addition, using our model, we found that tolerance induces 
a clear anti-inflammatory response, since IL-10 production 
was unchanged in tolerant animals and pro-inflammatory 
cytokines were reduced. Although a reduction in IL-10 
production in tolerant animals during terminal LPS chal-
lenge has been described previously, some investigators 
have found either increases or no change (4,5). These 
discrepancies require us to carefully characterize our LPS 
tolerance model. The anti-inflammatory cytokine IL-10 not 
only deactivates macrophages and neutrophils but also 
has the ability to alter the type and phase of the immune 
response (17). The diversity of biologic responses medi-
ated by cytokines requires a fuller understanding of their 
regulation during homeostasis and in various pathological 
conditions. 
We can avoid an intense inflammatory response using 
tools to induce a pre-existing state of tolerance. The inflam-
matory response evoked in order to eliminate bacteria is 
mediated by cytokines that govern the release of enzymes 
(e.g., metalloproteinases), as well as by those that regu-
late phagocytosis, oxidative stress, and nitrosative stress 
(18,19). Proper immune function relies on anti-inflammatory 
cytokines to appropriately target physiological responses 
to bacteria. For instance, IL-6 and IL-10 act on B cell dif-
ferentiation and increase antibody production (17,20,21), 
although appropriate amounts of anti- and pro-inflammatory 
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cytokines are necessary (11). Sepsis progresses via an 
exacerbated inflammatory response, including tissue ne-
crosis and leukocyte apoptosis (11,22). Therefore, sepsis 
is an inappropriate strategy to eliminate invading microor-
ganisms (11,22). In our study, spleen volume increased in 
tolerant animals, which, as we showed using cell counts 
and cytometry, reflects an increased number of immune 
cells. Patients and animals deficient in specific immune 
cells are more susceptible to infection and death (23,24). In 
addition, Hotchkiss and Karl (22) showed that apoptosis of 
lymphocytes and dendritic cells are associated with death 
from sepsis in human patients. This observation was con-
firmed in experimental studies in which apoptosis inhibition 
protected against polymicrobial infection (22). The increased 
number of lymphocytes and neutrophils in the spleens of 
tolerant animals in our study might signal a greater capacity 
on the part of the immune system to fight bacteria. In our 
LPS tolerance model, NOx and TBARS levels were not 
reduced in response to a lethal LPS challenge. Although 
production of NO in LPS tolerance has been controversial, 
Hirohashi and Morrison (25) showed that the release of NO 
depends on the tolerogenic LPS dose. We highlight here 
that protection against lethal LPS and CLP challenges found 
in LPS-tolerant animals is not caused by a reduction in NO. 
Despite some beneficial effects of NO inhibition, NO is a 
superoxide that the body uses to kill bacteria (11,26). These 
data raise the question of whether treating septic patients 
with antioxidant therapy is appropriate, or whether it is 
better to block the terminal effects of sepsis, i.e., reducing 
apoptosis and necrosis (11,22). 
In order to demonstrate the clinical relevance of LPS 
tolerance, we performed mortality studies using CLP, an 
accepted polymicrobial model of sepsis. Eichacker et al. 
(27) showed that anti-inflammatory interventions in sepsis 
were successful when the control group presented mortal-
ity rates greater than 60%. Lower mortality rates (40%) in 
controls were associated with no detectable protection 
by the various anti-inflammatory strategies proposed as 
experimental therapeutic approaches for the treatment of 
sepsis (27). In clinical trials, mortality from sepsis is gener-
ally 30-40% (27). This might explain why approaches that 
produce positive results in experimental studies routinely 
fail in clinical trials (27). The protection against death con-
ferred by LPS tolerance in our study was apparent not only 
in severe sepsis but also when mortality rates were lower 
in the control group. This suggests that LPS tolerance is 
effective in preventing death from sepsis in a wide range 
of disease severity. Some studies in the literature report 
that LPS tolerance provides protection against infections 
(4,14,15). However, that finding has not been confirmed, and 
some investigators have detected an increase in mortality 
(4,5). Comparing these studies is difficult because of the 
different models of tolerance, bacterial infection and fungal 
infection involved (4,5,14,15). However, as in our study, a 
preponderance of more recent reports have shown that LPS 
tolerance offers a protective effect in sepsis (4,5,14,15). We 
believe that the LPS tolerance model is characterized by 
changes in the immune system, and that these changes 
help it remain correctly regulated during sepsis. As a result, 
such models are not only useful for studying sepsis, but 
can point the way to new strategies for protecting patients. 
Although most studies in the literature have focused on 
ways to protect animals and patients by halting the clinical 
progression of sepsis, these strategies have failed to lower 
the mortality of sepsis (22).
Spleen cells in LPS tolerance
Differences in the qualitative and quantitative immune 
response to microbial stimulation might be critical for the 
understanding of the pathophysiology of sepsis (5,18). 
Although T-cell dysfunction is known to occur in sepsis, 
the increased release of cytokines has received far more 
attention than have changes in T-cell populations (28). Here, 
we observed that the spleens of tolerant mice contained 
more lymphocytes, monocytes, neutrophils, and pluripotent 
cells than did those of controls. It is known that T cells 
express Toll-like receptors, and that CD4+ T cells produce 
key cytokines and chemokines that can activate and attract 
macrophages and neutrophils to infection sites (28). Defec-
tive T-cell proliferation and cytokine secretion correlates 
with increased mortality in sepsis (22). In our study, LPS 
tolerance was not accompanied by similar defects in T-cell 
activity. Our results show that tolerance induction leads to 
changes in macrophages and lymphocytes, particularly T 
cells. In tolerant animals, the Th1 population of T lympho-
cytes was elevated, as evidenced by the cells containing 
the markers TNF-α and IFN-γ, indicating that the lympho-
cytes were activated. These results might seem to contrast 
with our findings vis à vis cytokine levels in blood plasma. 
However, it is important to note that baseline cytokine levels 
were higher in tolerant animals than in controls. However, 
when the animals were submitted to CLP, the tolerant mice 
produced lower amounts of cytokines. These results sug-
gest that the pre-activated lymphocytes were tempering 
the inflammatory response, as has been reported in the 
literature (29). 
To determine whether immune cells previously exposed 
to LPS maintain the properties of tolerance in a new host, 
cells were removed from the spleens and bone marrow 
of tolerant mice and injected into naive animals after CLP 
challenge. Significantly lower mortality rates were observed 
among animals that received transfers of either cell type. 
This effect was not observed in control experiments in 
which bone marrow or spleen cells from naive animals was 
injected instead. The control experiments helped exclude 
possible nonspecific effects of cellular transfer. The pool of 
cells obtained from the spleens and bone marrow of tolerant 
mice contained elevated levels of Oct-4, which participates 
in the epigenetic reprogramming of somatic cells into em-
bryonic stem cells and is also a marker for pluripotent cells 
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